Newsroom

Strive to Deliver Breakthroughs

  1. May 10, 2022

    Harbour BioMed to Present the Latest Progress of Next-Generation Anti-CTLA-4 Antibody HBM4003 at 2022 ASCO Annual Meeting

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — May 10, 2022   Harbour BioMed (the “Company”, HKEX: 02142), a global biopharmaceutical...

    View more
  2. May 06, 2022

    Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — May 6, 2022   Harbour BioMed (“HBM”, HKEX:02142), a global biopharmaceutical company co...

    View more
  3. April 14, 2022

    Harbour BioMed Appoints Dr. Humphrey Gardner as Chief Medical Officer

    CAMBRIDGE, Mass.; Suzhou, China; Rotterdam, Netherlands - April 14, 2022   Harbour BioMed (“HBM” or the “Company”; HKEX: 021...

    View more
  4. April 07, 2022

    Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022

    Cambridge, MA, Rotterdam, NL, Suzhou, CN— April 7, 2022   Harbour BioMed (“HBM”, “the Company”, HKEX: 02142), a globa...

    View more
  5. April 06, 2022

    Harbour BioMed Announces Poster Presentation on the Novel Bispecific Antibody PD-L1xCD40 at Upcoming American Association for Cancer Research (AACR) Annual Meeting

    Cambridge, MA, Rotterdam, NL, Suzhou, CN— April 6, 2022   Harbour BioMed (“HBM”, HKEX: 02142), a global biopharmaceutical company ...

    View more
  6. March 25, 2022

    Harbour BioMed Reports Full Year 2021 Financial Results: Two Late-stage Programs Are Accelerating Towards Commercialization with Robust Innovation and Globalization Capabilities

    CAMBRIDGE, Mass.; Suzhou, China; Rotterdam, Netherlands - March 25, 2022   Harbour BioMed (“HBM” or the “Company”; HKEX: 021...

    View more
  7. February 28, 2022

    Harbour BioMed Announces Approval for Phase I Trial of B7H4x4-1BB Bispecific Antibody in Australia

    Cambridge, MA, Rotterdam, NL, Suzhou, CN— February 28, 2022   Harbour BioMed (“HBM”, HKEX: 02142) announced that, it has been appr...

    View more
  8. February 21, 2022

    Harbour BioMed Announces IND Approval for Next-Gen Anti-TSLP Fully Human Monoclonal Antibody in Asthma

    Cambridge, MA, Rotterdam, NL, Suzhou, CN - February 21, 2022   Harbour BioMed (“HBM”, HKEX: 02142) announced that China National Me...

    View more
  9. January 24, 2022

    Harbour BioMed Announces Dosing of First Patient in Phase Ib/IIa Trial of Next-Generation Anti-CTLA-4 Antibody

    Cambridge, MA, Rotterdam, NL, Suzhou, CN— January 24, 2022   Harbour BioMed (“HBM”, HKEX: 02142) announced that, it has successful...

    View more
  10. January 13, 2022

    Harbour BioMed Completes the First Interim Analysis of Phase III Clinical Trial of Tanfanercept

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — January 13, 2022   Harbour BioMed (“HBM”, HKEX: 02142) announced that, the Company has ...

    View more